Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
EBX-102 by Enterobiotix for Irritable Bowel Syndrome: Likelihood of Approval
EBX-102 is under clinical development by Enterobiotix and currently in Phase II for Irritable Bowel Syndrome. According to GlobalData, Phase...
EBX-102 by Enterobiotix for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
EBX-102 is under clinical development by Enterobiotix and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)....
EBX-102 by Enterobiotix for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
EBX-102 is under clinical development by Enterobiotix and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)....
EBX-102 by Enterobiotix for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval
EBX-102 is under clinical development by Enterobiotix and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)....
EBX-102 by Enterobiotix for Myelodysplastic Syndrome: Likelihood of Approval
EBX-102 is under clinical development by Enterobiotix and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II...
EBX-102 by Enterobiotix for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
EBX-102 is under clinical development by Enterobiotix and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...